Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg

September 24, 2026 updated by: Miklos Schneider MD, PhD, Copenhagen University Hospital, Rigshospitalet

Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg. Phase 3 trials supported its use in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

The aim of this study was to estimate the incidence of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injections in an unselected cohort treated at a large tertiary referral center, and describe the presentation, management and outcome of the affected eyes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

3690

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Glostrup Municipality, Denmark, 2600
        • Rigshospitalet, Department of Ophthalmology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive patients who received at least 1 intravitreal aflibercept 8mg injection between 01/DEC/2024 and 30/NOV/2025 at the Department of Ophthalmology, Rigshospitalet, Denmark

Description

Inclusion Criteria:

  • >18 years of age
  • Have received at least 1 intravitreal aflibercept 8mg injection at our center
  • Follow-up period of at least 6 weeks after the injection

Exclusion Criteria:

  • Patients with incomplete medical records

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Received aflibercept 8mg intravitreal injections

intravitreal injection

Other Names:
  • aflibercept 8mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of IOI following an intravitreal aflibercept 8 mg injection
Time Frame: 01/DEC/2024 - 30/NOV/2025

Reported per patient, per eye and per injection

01/DEC/2024 - 30/NOV/2025

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anatomical IOI phenotype
Time Frame: 01/DEC/2024 - 30/NOV/2025

Described after the SUN classification system

01/DEC/2024 - 30/NOV/2025
Time from injection to IOI symptom onset
Time Frame: 01/DEC/2024 - 30/NOV/2025

Described in days

01/DEC/2024 - 30/NOV/2025
Disease duration of IOI
Time Frame: 01/DEC/2024 - 30/NOV/2025

Described in days

01/DEC/2024 - 30/NOV/2025
Treatment strategy after the IOI event
Time Frame: 01/DEC/2024 - 30/NOV/2025

Description of the type of drug or intervention used

01/DEC/2024 - 30/NOV/2025
Functional outcome after the IOI event
Time Frame: 01/DEC/2024 - 30/NOV/2025

Described in logMAR best-corrected visual acuity

01/DEC/2024 - 30/NOV/2025

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparisons by demographic characteristics, diagnosis and treatment status
Time Frame: 01/DEC/2024 - 30/NOV/2025

Described as exploratory descriptive analysis

01/DEC/2024 - 30/NOV/2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 20, 2026

Primary Completion (Actual)

August 10, 2026

Study Completion (Actual)

September 14, 2026

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

September 24, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • p-2026-21310

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Raw data sharing with third parties was not approved for this project.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.